No Data
No Data
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Hailansheng Pharmaceutical (688302.SH): a net loss of 0.1 billion yuan in the first half of the year.
Haichuang Pharmaceutical (688302.SH) announced its interim report for the first half of 2024, with revenue of 0.1097 million yuan; net loss attributable to shareholders of listed companies was -0.1 billion yuan, a narrower loss compared to the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was -0.11 billion yuan; basic earnings per share was -1.01 yuan.
HaiChuang Pharmaceutical (688302.SH): The clinical trial of HP560 tablets for the treatment of bone marrow fibrosis has obtained a drug clinical trial approval notice.
On July 24th, Gelunhui announced that Haichuang Pharmaceutical (688302.SH) received the Drug Clinical Trial Approval Notice issued and approved by the Drug Evaluation Center of the China National Medical Products Administration, agreeing to conduct clinical trials of HP560 tablets for the treatment of myelofibrosis. As of the date of this announcement, no similar target product has been approved for listing both domestically and overseas.
Hinova Pharmaceuticals Gets US FDA's Nod to Trial HP537 Tablets
Express News | Hinova Pharma Receives U.S. FDA Study May Proceed Notification for Phase I/II Clinical Trial of HP537 for Treatment of Hematological Malignancies
No Data
No Data